DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor

[1]  Ryan J. Schmidt,et al.  Expanding the spectrum of dicer1-associated sarcomas , 2019, Modern Pathology.

[2]  K. Ichimura,et al.  Two cases of primary supratentorial intracranial rhabdomyosarcoma with DICER1 mutation which may belong to a “spindle cell sarcoma with rhabdomyosarcoma-like feature, DICER1 mutant” , 2019, Brain Tumor Pathology.

[3]  Angad P. Singh,et al.  Germline DICER1‐mutant intracranial sarcoma with dual chondroid and spindle cell morphology and pulmonary metastases treated with multimodal therapy , 2019, Pediatric blood & cancer.

[4]  W. Foulkes,et al.  An update on the central nervous system manifestations of DICER1 syndrome , 2019, Acta Neuropathologica.

[5]  David T. W. Jones,et al.  Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1 , 2019, Acta Neuropathologica.

[6]  M. Kool,et al.  ETMR-like infantile cerebellar embryonal tumors in the extended morphologic spectrum of DICER1-related tumors , 2018, Acta Neuropathologica.

[7]  Isabelle Salmon,et al.  Methods of measurement for tumor mutational burden in tumor tissue. , 2018, Translational lung cancer research.

[8]  David T. W. Jones,et al.  Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations , 2018, Acta Neuropathologica.

[9]  S. Bens,et al.  Multiple DICER1‐related tumors in a child with a large interstitial 14q32 deletion , 2018, Genes, chromosomes & cancer.

[10]  Gretchen M. Williams,et al.  DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies , 2018, Clinical Cancer Research.

[11]  Gretchen M. Williams,et al.  Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma / DICER1 syndrome: a unique variant of the two-hit tumor suppression model , 2018, F1000Research.

[12]  K. Cole,et al.  Comprehensive Analysis of Hypermutation in Human Cancer , 2017, Cell.

[13]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[14]  Jeffrey K. Mito,et al.  Role of Histone H3K27 Trimethylation Loss as a Marker for Malignant Peripheral Nerve Sheath Tumor in Fine-Needle Aspiration and Small Biopsy Specimens , 2017, American journal of clinical pathology.

[15]  J. Ragoussis,et al.  Sequencing of DICER1 in sarcomas identifies biallelic somatic DICER1 mutations in an adult-onset embryonal rhabdomyosarcoma , 2017, British Journal of Cancer.

[16]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[17]  L. Macconaill,et al.  Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. , 2017, Archives of pathology & laboratory medicine.

[18]  Marian Harris,et al.  Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.

[19]  Gretchen M. Williams,et al.  Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in DICER1 syndrome: a unique variant of the two-hit tumor suppression model. , 2015, F1000Research.

[20]  M. Gullerová,et al.  Swiss army knives: non-canonical functions of nuclear Drosha and Dicer , 2015, Nature Reviews Molecular Cell Biology.

[21]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[22]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[23]  W. Foulkes,et al.  DICER1: mutations, microRNAs and mechanisms , 2014, Nature Reviews Cancer.

[24]  J. Lupski,et al.  Germ-line and somatic DICER1 mutations in pineoblastoma , 2014, Acta Neuropathologica.

[25]  Trevor J Pugh,et al.  Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences , 2014, Oncogene.

[26]  P. Maeder,et al.  Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations , 2014, Acta Neuropathologica.

[27]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[28]  Arjun Bhutkar,et al.  In vivo structure-function analysis of human Dicer reveals directional processing of precursor miRNAs. , 2012, RNA.

[29]  Gretchen M. Williams,et al.  DICER1 Mutations in Familial Pleuropulmonary Blastoma , 2009, Science.

[30]  S. Friend,et al.  Pleuropulmonary blastoma: A marker for familial disease , 1996 .

[31]  T. Arndt,et al.  In vivo , 2019, Springer Reference Medizin.

[32]  M. O'sullivan,et al.  Anaplastic sarcomas of the kidney are characterized by DICER1 mutations , 2018, Modern Pathology.

[33]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[34]  S. Ogino,et al.  Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing. , 2017, The Journal of molecular diagnostics : JMD.

[35]  C. Fletcher,et al.  Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics , 2016, Modern Pathology.